Truist raises Ideaya Biosciences stock price target on trial data

IDEAYA Biosciences received a bullish analyst update as Truist raised its price target to $65 from $60 and maintained a Buy rating after positive darovasertib combination data. The therapy posted a 6.9-month median progression-free survival and 37% objective response rate in metastatic uveal melanoma, supporting Truist’s view of potential accelerated approval by late 2026 or early 2027. Truist also lifted peak revenue estimates to more than $800 million in metastatic uveal melanoma and about $1.7 billion across all settings.

Analysis

IDYA is moving from a “science story” to a “path-to-approval” story, which is the key inflection point for biotech multiples. The market is likely underestimating how much a clean pivotal readout compresses financing risk: with a credible accelerated-approval path, the company can likely fund the next leg of development on materially better terms, and that optionality alone can sustain multiple expansion even before launch revenue is visible.

The second-order winner may be the platform rather than the asset. If darovasertib can be positioned across biomarker-defined subgroups, the addressable market expands without needing a wholesale commercial rebuild, which raises the probability that strategic buyers start valuing IDYA as a pipeline stack instead of a single-asset binary. That matters because oncology M&A is increasingly driven by de-risked registrational assets with clear label expansion paths, not just peak sales.

The main risk is that investors are extrapolating a clean approval path from an efficacy signal that still needs regulatory translation. In biotech, the gap between a strong phase readout and a commercially durable label is where deals get re-rated lower: confirmatory trial design, comparator choice, and durability of benefit will matter over the next 6-12 months. A weaker-than-expected benefit-risk debate or a slower FDA review could compress gains quickly even if the stock rerates in the near term.

Consensus may also be too focused on metastatic uveal melanoma alone and not enough on how pipeline collaboration optionality changes the valuation floor. If the market starts assigning even a modest probability to broader combination utility, today’s move may still be early rather than exhausted. But if follow-up catalysts fail to show incremental data breadth, this becomes a classic one-shot biotech pop that fades as the story de-risks into a more ordinary approval grind.

Key Decisions for Investors

• Long IDYA into the next regulatory catalyst, but size it as a 6-12 month event-driven position rather than a core hold; risk/reward is attractive if the market continues to price in accelerated approval, but downside is sharp if FDA path or durability concerns emerge.
• Use call spreads in IDYA instead of outright stock for the next 3-6 months; this captures rerating from approval probability while limiting gap risk if the stock gives back post-readout enthusiasm.
• If long IDYA, pair it against a basket of higher-quality large-cap oncology names to isolate binary trial risk; the trade works if small/mid-cap oncology keeps rewarding de-risked assets more than diversified platforms.
• Take profits on strength into any pre-approval squeeze; once consensus fully accepts the regulatory path, multiple expansion typically slows and the stock shifts from data-driven to execution-driven.
• Monitor for strategic interest from larger oncology players; if a collaboration or licensing transaction appears, add on confirmation because it would validate broader platform value beyond the lead indication.